ArticleMolecular therapy : the journal of the American Society of Gene Therapy2011
Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy.Korean journal of clinical oncology · 2025Review
- Tumor necrosis factor superfamily signaling: life and death in cancer.Cancer metastasis reviews · 2024Review
- The role of the BTLA-HVEM complex in the pathogenesis of breast cancer.Breast cancer (Tokyo, Japan) · 2024Review
- Can we consider soluble herpes virus entry mediator (sHVEM) as a tumor marker?Caspian journal of internal medicine · 2022Article
- VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment.JCI insight · 2021Article
- Article
- Emerging Immunotherapy for Acute Myeloid Leukemia.International journal of molecular sciences · 2021Review
- The Role of B and T Lymphocyte Attenuator in Respiratory System Diseases.Frontiers in immunology · 2021Review
- LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures.Oncoimmunology · 2020Article
- High expression of herpes virus entry mediator is associated with poor prognosis in clear cell renal cell carcinoma.American journal of cancer research · 2019Article
- T cell exhaustion: from pathophysiological basics to tumor immunotherapy.Cell communication and signaling : CCS · 2017Review
- Cardiotoxicity of immune checkpoint inhibitors.ESMO open · 2017Review
- Review
- Combination cancer immunotherapies tailored to the tumour microenvironment.Nature reviews. Clinical oncology · 2016Review
- BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine.Oncotarget · 2015Article
- Inhibitory receptors as targets for cancer immunotherapy.European journal of immunology · 2015Review
- OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Frontiers in oncology · 2015Review
- Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators.Frontiers in immunology · 2015Review
- The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Vaccines that aim to expand tumor-specific CD8(+) T cells have yielded disappointing results in cancer patients although they showed efficacy in transplantable tumor mouse models. Using a system that more faithfully mimics a progressing cancer and its immunoinhibitory microenvironment, we here show that in transgenic mice, which gradually develop adenocarcinomas due to expression of HPV-16 E7 within their thyroid, a highly immunogenic vaccine expressing E7 only induces low E7-specific CD8(+) T-cell responses, which fail to affect the size of the tumors. In contrast, the same type of vaccine expressing E7 fused to herpes simplex virus (HSV)-1 glycoprotein D (gD), an antagonist of the coinhibitory B- and T-lymphocyte attenuator (BTLA)/CD160-herpes virus entry mediator (HVEM) pathways, stimulates potent E7-specific CD8(+) T-cell responses, which can be augmented by repeated vaccination, resulting in initial regression of even large tumor masses in all mice with sustained regression in more than half of them. These results indicate that active immunization concomitantly with blockade of the immunoinhibitory HVEM-BTLA/CD160 pathways through HSV-1 gD may result in sustained tumor regression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.